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Abstract Resveratrol, a naturally occurring polyphenol,
has been reported to be an anti-tumor and chemopreventive
agent. Recent data show that it may also exert anti-angio-
genic effects. We hypothesized that the anti-angiogenic
activityofresveratrolmaybecausedbymodulationoftumor
cell release of thrombospondin-1 (TSP1) and vascular
endothelial growth factor (VEGF) into the extracellular
matrix,leadingtovascularendothelialcell(VEC)apoptosis.
We therefore evaluated the effects of resveratrol on mela-
nomacelllinesco-culturedwithvascularendothelialcellsin
monolayer and in three dimensional spheroids. We found
that resveratrol stimulated isolated VEC proliferation, while
it caused growth inhibition of VECs grown with melanoma
cells in three-dimensional co-culture. This effect was asso-
ciated with increased melanoma cell expression of tumor
suppressor protein 53 and matrix protein TSP1, as well as
decreased hypoxia-driven expression of hypoxia inducible
factor-1a and inhibition of VEGF production.
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Introduction
Angiogenesis, the creation of new blood vessels, is critical
for cancer development and progression and is associated
with an invasive phenotype and poor prognosis [1, 2].
Angiogenesis is regulated by numerous activators and
inhibitors [3, 4]. As malignant cells outgrow their oxygen
supply, hypoxia inducible factor-1a (HIF-1a) is stabilized
in response to decreased oxygen tension [5, 6]. HIF-1a up-
regulates several pro-angiogenic factors [7] such as vas-
cular endothelial growth factor (VEGF) [8, 9]. VEGF
promotes angiogenesis by stimulating vascular endothelial
cells to migrate towards and into hypoxic zones of the
tumor while protecting them from apoptotic death during
migration [10, 11]. Increased VEGF expression has also
been associated with increased metastases and poorer sur-
vival [12–15].
Hypoxia inducible factor-1a has been found to bind to
the tumor suppressor protein p53 (p53) [16–18]. Like HIF,
p53 is stabilized under hypoxic conditions, although they
have somewhat opposing actions with regards to angio-
genesis [19, 20]. p53 has been shown to suppress angio-
genesis by up-regulating transcription of anti-angiogenic
factors, including thrombospondin-1 (TSP1) [21, 22].
TSP1, a natural inhibitor of angiogenesis, counterbalances
the effects of VEGF on endothelial cells [23]. TSP1
binding to endothelial cell CD36 receptors, or other
receptors such as CD47, leads to downstream apoptosis
[24, 25]. We previously established a relationship between
p53, TSP1, and angiogenesis in clinical tumor specimens
of melanoma, ovary, and prostate [26–28]. Our data dem-
onstrated that the presence of mutant (mt) p53 was sig-
niﬁcantly associated with loss of wild-type (wt) p53
function manifested by decreased TSP1 expression and
increased angiogenesis. Patients with lower TSP1 had
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of metastatic melanoma specimens demonstrated p53
accumulation as measured by IHC [26]. This was
initially interpreted to be caused by mutations in geno-
mic p53 that lead to a prolonged protein half life
[26, 29]. However, it has subsequently come to light that
p53 mutations are rare in melanoma, perhaps on the
order of 10%, suggesting that protein–protein interactions
affected by p53 phosphorylation or acetylation status
may be involved in p53 accumulation in melanoma
[30–37].
Resveratrol (trans-3,40,5-trihydroxystilbene) is a poly-
phenol compound found naturally in grapes, red wine,
peanuts, blueberries, cranberries, eucalyptus, and many
other plants. It is a phytoalexin and an antioxidant [38, 39].
Resveratrol has been found to inhibit events associated
with tumor initiation, promotion, and progression [40, 41].
It has been shown to induce cancer cell apoptosis and/or
senescence [42–45]. Recent data suggest that resveratrol
exhibits natural anti-angiogenic activity [46–48]. Mecha-
nisms of resveratrol’s anti-angiogenic effects include
inhibition of hypoxia-induced accumulation of HIF-1a [49,
50] and down-regulation of VEGF [50, 51]. It has also been
demonstrated that resveratrol can increase p53 function in
a dose-dependent manner in both cancerous and non-
cancerous cell lines [52–54].
Although resveratrol has been reported to confer a
protective effect against oxidized low-density lipoprotein
damage of endothelial cells [55], enhance endothelial cell
proliferation at low doses [56], and induce the proliferation
and migration of endothelial progenitor cells [57], we
hypothesize that resveratrol acts as an antiangiogenic
compound indirectly by simultaneously increasing
expression of TSP1 and decreasing expression of VEGF in
cancer cells, thereby inhibiting angiogenesis through vas-
cular endothelial cell (VEC)-cancer cell and VEC-matrix
protein interactions.
In order to interrogate the relevance of such interac-
tions to the effects of antiangiogenic agents, we devel-
oped an in vitro model of tumor angiogenesis that
incorporates VECs into three-dimensional cancer spher-
oids [58]. VECs are ﬂuorescently transduced to identify
and monitor their migration into tumor spheroids as well
as their response to treatment. Whereas numerous models
for angiogenesis exist, few allow for the direct analysis
of VEC-cancer cell and VEC-stromal interactions. Here
we show that resveratrol stimulates VEC growth in
monolayer culture but causes a decrease in VEC survival
in the three-dimensional tumor co-culture as a result
of shifting the ratio between matrix TSP1 and VEGF
expression. In this study we report ﬁrst evidence that
resveratrol treatment results in increased levels of TSP1,
a downstream target of p53.
Materials and methods
Cell culture
YUZAZ6 (Dr. Halaban, Yale, New Haven CT) and M14
melanoma cell lines were maintained in RPMI 1640
medium (Invitrogen, Carlsbad CA) supplemented with
10% fetal bovine serum (FBS; Gemini Bio-Products West
Sacramento CA) and 1% penicillin/streptomycin solution
(PS; Invitrogen, Carlsbad CA). A375 melanoma cells
(ATCC, Manassas VA) were maintained in Advanced
Minimum Essential Medium (AMEM; Invitrogen, Carlsbad
CA) supplemented with 2 mM L-glutamine, 10% FBS, and
1% PS. HMVECad (Cascade Biologics, Portland OR),
HUVEC, or HAAE1 (both ATCC, Manassas VA) endo-
thelial cells were maintained in F12/K media (Invitrogen,
Carlsbad CA) supplemented with 5% FBS, 0.2 lg/ml
hydrocortisone (Sigma, St. Louis MO), 5 ng/ml EGF,
0.5 ng/ml VEGF, 10 ng/ml FGF, 20 ng/ml IGF (all from
Peprotech, Rocky Hill NJ), 1 lg/ml ascorbic acid (Sigma,
St. Louis MO), and 1% PS. Unless otherwise noted, cells
were grown under standard normoxic (21% O2) conditions
at 37C in a 5% CO2 incubator. Hypoxic conditions were
generated in Forma Series II water jacketed incubator
(Thermo Fisher Scientiﬁc, Marietta, OH) set at 2% O2,5 %
CO2, and balance N2.
Fluorescent labeling of endothelial cells
The retroviral vector pBMN-mcherry (Provided as a gift by
Dr. Steven George, University of California Irvine, Irvine,
CA) was used to transduce HMVECad endothelial cells
with RFP for two consecutive days as described previously
[59]. Brieﬂy, Phoenix cells (Orbigen, San Diego CA) were
transfected for a period of 6 h with pBMN-cherry vector
using Lipofectamine 2000 (Invitrogen, Carlsbad CA) per
manufacturer’s instructions. Viral supernatants were col-
lected at 48 and 72 h, sterile ﬁltered to remove ﬂoating
cells, mixed with polybrene at a ﬁnal concentration of
5 lg/ml, and added fresh to HMVECad cells for a period of
6 h. The viral supernatant was replaced with fresh com-
plete EC media overnight and the procedure was repeated
on day two. Cells expressing mcherry were sorted by
FACSaria (Becton Dickinson, San Jose, CA).
Thrombospondin-1 knockdown
Three Expression Arrest GIPZ lentiviral shRNAmir clones
for THBS1 and one non-silencing control (Open Biosys-
tems, Huntsville, AL) were cultured overnight and plas-
mids were puriﬁed using a Plasmid Mini Kit (Qiagen,
Valencia, CA). A375 cells were transfected using Arrest-In
(Open Biosystems, Huntsville, AL) per manufacturer’s
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123instructions. Initial selection was carried out based on
puromycin (InvivoGen, San Diego, CA) resistance and GFP
expression. Puromycin resistance was deﬁned as survival
afterexposureto0.5 lg/mlpuromycinforaperiodof5 days.
GFP expression was deﬁned as GFP ﬂuorescence intensity
109 greater than auto-ﬂuorescence as determined by
FACSaria (BD Biosciences, San Jose, CA). Individual
clones were then isolated, grown up, and screened for TSP1
knockdown by ELISA as described below.
Treatment with resveratrol
A 100 mM stock solution of resveratrol (Sigma, St. Louis,
MO) was prepared in DMSO and stored as frozen aliquots
at -20C. For treatment of cells, resveratrol was further
diluted in appropriate cell culture media.
XTT assay for metabolic activity
Cells were plated into 96 well tissue culture plates at a
density of 3,000 cells per well and allowed to attach
overnight. Cells were treated with resveratrol for a period
of 72 h and metabolic activity was measured using the
XTT assay. Brieﬂy, 75 ll of XTT reagent (Sigma,
St. Louis, MO) was added to each well already containing
150 ll of media. Plates were incubated for 4 h and optical
densities were read at a wavelength of 490 nm with a
reference wavelength of 630 nm.
Cell lysates
Cells were lysed using RIPA buffer (Sigma, St. Louis, MO)
supplemented with 1% Halt Protease Inhibitor Cocktail
with EDTA (Pierce, Rockford, IL) per manufacturer’s
instructions and 0.2% PMSF (Sigma, St. Louis, MO) and
cleared by centrifugation.
Conditioned media experiments
Forty-eight hour conditioned media was collected and
syringe ﬁltered through a 0.22 lm PES membrane (Milli-
pore, Billerica, MA) to remove any cells in suspension.
Endothelial cells were plated overnight, then two volumes
of conditioned media was added to the cells and incubated
for an additional 72 h.
Western blotting
Protein bands were resolved on 10–20% Tricine SDS–
PAGE gels (Invitrogen, Carlsbad, CA), transferred to
PDVF Immobilon-FL membranes (Millipore, Billerica,
MA), and blocked for 1 h using a 5% milk solution pre-
pared in phosphate buffered saline (Invitrogen, Carlsbad,
CA) supplemented with 0.05% Tween 20 (PBS-T; Sigma,
St. Louis, MO), followed by an overnight incubation with
primary antibody at 4C. Antibody dilutions and conditions
were as follows: p53 1:500 (Santa Cruz clone DO-1) and
TSP1 1:50 (clone 8A6b Novocastra/Leica, Bannockburn,
IL). Membranes were incubated with HRP conjugated anti-
biotinylated (Cell Signalling, Danvers, MA) and goat anti-
mouse IgG:HRP (Stressgen, Ann Arbor, MI) in 5% milk
for 1 h at RT and developed using the SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Blots were imaged on a Kodak Image Station 2000MM.
ELISAs
VEGF, TSP1, HIF-1a, and p53 levels were measured using
DuoSet IC ELISA kits (R&D system, Minneapolis, MN)
per manufacturer’s instructions.
RT-PCR
Total RNA was extracted from one-third of the pelleted
cells using Qiagen RNeasy Mini kit per manufacturer’s
protocol (Qiagen, Valencia, CA). One microgram of total
RNA was reverse transcribed using the Superscript III First
Strand kit (Invitrogen, Carlsbad, CA). Reverse transcrip-
tion was carried out for 3 min at 85C, 60 min at 42C, and
10 min at 92C. Human THBS1 cDNA real-time PCR was
performed using an ABI 7000 (Applied Biosystems, Foster
City, CA). Approximately 25 ng of reverse-transcribed
cDNA per sample was used with a start cycle of 2 min at
50C and 10 min at 95C, and 40 cycles of 15 s at 95C
and 1 min at 60C. THBS1 and GAPDH primers were used
with Taqman Universal PCR Mastermix (Applied Biosys-
tems, Foster City, CA) to perform Real-time PCR. Relative
quantiﬁcation (RQ) values were expressed using the for-
mula: (2
Ctr - Ctt) where Ctr - Ctt represents the difference
between delta Ct between the reference sample (untreated
control) and tested samples (resveratrol treatment). Delta
Ct is the difference between mean Ct values of samples in
the target wells and those of endogenous control for the
same wells (GAPDH). Values are expressed as fold
increases relative to reference sample (untreated control).
Production of spheroids
Serum-free RPMI 1640 medium was prewarmed to 60C,
125 ml of media was added to 3.0 g of autoclaved meth-
ylcellulose (Sigma, St. Louis, MO), and the mixture was
stirred continuously for 20 min under aseptic conditions.
The methylcellulose was diluted with 125 ml of media at
room temperature (RT) and stirred for an additional 2 h at
4C. The viscous solution was aliquoted into tubes and
centrifuged at 25009g at RT for 2 h. The clear, highly
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123viscous supernatant was removed and stored at 4C for
future use.Methylcellulosewas never warmed and re-stored
at 4C. 300,000 cells were re-suspended in 10 ml of media
supplementedwith20%methocelstock.Avolumeof100 ll
of cell suspension was aliquoted into each well of a 96 well
round bottom suspension culture plate (Greiner Bio One,
Monroe, NC) and incubated at 37C, 5% CO2 in a humidi-
ﬁed atmosphere. Optimal spheroid formation for some cell
lines required modiﬁcation in methocel concentration or
FBS supplementation or a decrease in cell density.
Effect of resveratrol on angiogenesis in vitro
A 1:1 ratio of pBMN-mcherry transduced HMVECad and
untransfected or shRNA transfected tumor cells were
grown as spheroids for 3 days and subsequently treated
with resveratrol for 3 days. At the end of treatment, eight
spheroid co-cultures were pooled and disaggregated in
1 ml Accumax (Innovative Cell Technologies, San Deigo,
CA). A standard volume of 50 ll of CountBright beads
(Invitrogen, Carlsbas, CA) was added to each pooled
sample to aid in cell enumeration. After disaggregation,
cells were washed once in annexin V binding buffer
(140 mM NaCl, 4 mM KCl, 0.75 mM MgCl2,1 0 m M
HEPES, 1.5 mM CaCl2, pH 7.4). Annexin V binding
(BD Biosciences, San Jose, CA) was analyzed per manu-
facturer’s recommendation. Brieﬂy, annexin V-FITC was
added to the cell suspension at a 1:20 dilution and incu-
bated for 15 min. Samples were then diluted ﬁvefold with
annexin V binding buffer and run by ﬂow cytometry on a
FACSaria (BD Biosystems, San Jose, CA). Endothelial
cells were distinguished based on their ﬂuorescent label
and cells were enumerated based on a ratio of endothelial
cells to CountBright beads per sample.
Statistical analysis
GraphPadInstatversion3.0andPrismversion4.0(GraphPad
software, San Diego, CA) were employed for data analysis.
Calcusyn software (Biosoft, Ferguson, MO) was used to
determine cell line IC50 values. Data are represented as mean
values±SDforthreeseparateexperiments.One-tailedpaired
student’s t-tests were used to determine statistical signiﬁ-
cance. P-values\0.05 were considered signiﬁcant.
Results
Effect of resveratrol on cell viability
Melanoma cell lines (A375, M14, and YUZAZ6) were
treated with resveratrol for a period of 72 h. All cell lines
showed a dose-dependent decrease in metabolic activity as
measured by the XTT assay (Fig. 1a). A375 cells were the
most sensitive to resveratrol with an IC50 dose of
28.79 lM, YUZAZ6 cells had an IC50 dose of 36.46 lM,
and M14 cells were the most resistant with an IC50 dose of
103.44 lM. Resveratrol was not found to cause a dose-
dependent dependent decrease in the viability of any of the
three endothelial cell lines tested after a 72 h treatment
period (Fig. 1b). Resveratrol was found to have a prolif-
erative effect on HAAE1 cells.
Resveratrol decreased survival of VECs in an in vitro
angiogenesis model
Angiogenesis was evaluated as a function of endothelial
cell survival in our three-dimensional spheroidal co-culture.
M14 cells could not be tested because they did not form
uniform spheroids. The WM3211 cell line which formed
adequate spheroids was therefore utilized as a third mela-
noma cell line. Resveratrol treatment (50 lM, 48 h) caused
a decrease in endothelial cell viability when grown in
co-culture with A375, YUZAZ6, or WM3211 melanoma
cells (Fig. 2).
Increased p53 and TSP1 expression after resveratrol
treatment
We compared the effects of resveratrol on the YUZAZ6
melanoma line that expresses wt p53 with the M14 line that
Fig. 1 Effect of resveratrol on cell line viability. Dose response of
various melanoma (a) or endothelial (b) cell lines exposed to
resveratrol for 72 h as determined by XTT. Performed in triplicate.
Error bars represent ±SD
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123expresses mt p53 [60]. YUZAZ6 and M14 cells were
treated with resveratrol and their protein expression
assayed by western blot. Both wt and mt p53 were detected
by the anti-p53 clone DO-1. Cell lines expressing wt p53
showed a time- and dose- dependent increase in p53 and
TSP1 band intensity (Fig. 3). On the other hand, the M14
cell line that expresses mt p53 showed decreased p53
staining intensity but increased TSP1 band intensity.
Representative blots of the wild-type p53 melanoma cell
line YUZAZ6 (Fig. 3a, b) and mutant p53 melanoma cell
line M14 (Fig. 3c, d) are shown. We found this phenom-
enon to be reproducible by western blot in other melanoma
cell lines including SKMEL5 and WM3211 as well as in
breast cancer cell lines (data not shown). To show that the
increase in TSP1 expression levels occurred at a tran-
scriptional level, we performed RT-PCR on A375 cells
treated with resveratrol and compared it to untreated
control cells. We found that treatment with 50 lM resve-
ratrol for 48 h caused a 1.7-fold increase in thrombo-
spondin-1 (gene: THBS1) mRNA expression and was
considered signiﬁcant with a P-value of 0.0019 (Fig. 3e).
In order to more accurately assess the changes in p53
levels with resveratrol treatment and the effect of hypoxia
Fig. 2 Effect of resveratrol on HMVEC viability in a three-dimen-
sional co-culture model of tumor angiogenesis, when co-cultured with
A375 (a) YUZAZ6 (b) or WM3211 (c) cells, as determined by ﬂow
cytometry. Performed in triplicate. Error bars represent ±SD
Fig. 3 Effect of resveratrol by western blot. Dose dependent
response of YUZAZ6 wild-type p53 line (a) or M14 mutant p53
line (c) to resveratrol at 72 h. Time dependent response of YUZAZ6
wild-type p53 line to 30 lM resveratrol (b) or M14 mutant p53 line to
50 lM resveratrol (d). Effect of resveratrol by RT-PCR. Increased
thrombospondin expression is caused by a transcriptional increase in
THBS1 (e). Performed in triplicate. Error bars represent ±SD
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123on p53 stabilization, A375, M14, and YUZAZ6 cells
grown under both normoxic and hypoxic (2% O2) condi-
tions were exposed to 50 lM resveratrol for a period of
48 and 72 h and protein expression was determined by
ELISA. Both hypoxic conditions and resveratrol resulted in
wt p53 accumulation in YUZAZ6 and A375 cell lines,
while resveratrol treatment led to decreased mt p53
accumulation in the M14 cell line (Fig. 4a–c). For A375
cells, the degree of resveratrol-induced accumulation
of p53 under both normoxic and hypoxic conditions
Fig. 4 Effect of resveratrol on expression of p53 (a–c), HIF-1a (d–f),
or VEGF (g–i) on normoxic and hypoxic monolayers as determined
by ELISA in A375 (a, d, g), M14 (b, e, h), or YUZAZ6 (c, f, i)
melanoma cell lines. All cells were lysed after 48 h treatment with
resveratrol with the exception of M14 cells that were lysed at 72 h for
evaluation of p53 (b). Performed in triplicate. Error bars represent
±SD
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123was considered signiﬁcant (P = 0.0331 and P = 0.0011
respectively), while hypoxia-induced accumulation of p53
was not signiﬁcant (P[0.05). For YUZAZ6 cells, resve-
ratrol-induced or hypoxia-induced accumulation of p53
alone was not signiﬁcant, but accumulation of p53 induced
by resveratrol under hypoxic conditions was considered
signiﬁcant (P = 0.0144). For M14 cells, only the resvera-
trol-induced decrease in p53 accumulation under normoxic
conditions was considered signiﬁcant (P = 0.0373).
Inhibition of HIF1 stabilization and VEGF expression
by resveratrol
All three cell lines were also assayed for HIF-1a (Fig. 4d–f)
and VEGF (Fig. 4g–i) expression after a 48 h period of
hypoxia with or without resveratrol. Melanoma cell lines
were found to have increased baseline levels of HIF-1a
stabilization, likely secondary to ROS production [6].
Hypoxia was found to cause additional stabilization of HIF-
1a in all three cell lines, but the degree of HIF-1a accumu-
lation was found to be signiﬁcant only for the A375 cell line
(P = 0.030) with a trend toward signiﬁcance in the other
lines (M14, P = 0.1102 and YUZAZ6, P = 0.0948). Res-
veratrol signiﬁcantly inhibited normoxic stabilization of
HIF-1a in M14 and YUZAZ6 cell lines (P = 0.0303 and
P = 0.0163 respectively), but did not inhibit the low base-
line levels of A375 cell line HIF-1a. Resveratrol also
inhibited hypoxia-induced stabilization of HIF-1a in all
three cell lines, which was signiﬁcant for A375 and
YUZAZ6 cell lines, with a trend for M14 cells (A375,
P = 0.0389; YUZAZ6, P = 0.0317; M14, P = 0.0783).
As expected, hypoxia-induced accumulation of HIF-1a
was closely followed by a signiﬁcant increase in VEGF
expression for all cell lines (A375, P = 0.0007; M14,
P=0.023; YUZAZ6, P=0.0332). Resveratrol down-
regulated both hypoxia-induced and normoxic baseline
VEGF. This down-regulation was signiﬁcant under norm-
oxic conditions for A375 (P=0.0237) and YUZAZ6
(P=0.0291) cell lines, and signiﬁcant under hypoxic
conditions for all three cell lines (A375, P=0.0101; M14,
P=0.0311; YUZAZ6, P=0.0014). HIF-1a expression
was strongly and signiﬁcantly associated with VEGF levels
for all three cell lines (A375: r = 0.9649, P=0.0351;
M14: r = 0.9943, P=0.0057; YUZAZ6: r = 0.09722,
P=0.0228).
Effect of resveratrol on HIF-1a, VEGF, p53,
and TSP1 in melanoma spheroids
A375 and YUZAZ6 cells were grown as spheroids for 72 h
and treated with resveratrol for an additional 72 h. M14
cells do not form uniform spheroids using our spheroid-
formation method and were not assayed. Spheroids were
lysed and assayed for HIF-1a, VEGF, p53, and TSP1 by
ELISA (Fig. 5a–h). We found that resveratrol decreased
spheroid-related stabilization of HIF-1a in both A375 and
YUZAZ6 cell lines. The decrease in HIF-1a stabilization
was found to be signiﬁcant in both cell lines (A375,
P=0.0004; YUZAZ6, P=0.0112). Inhibition of HIF-1a
stabilization by resveratrol was also associated with
decreased VEGF expression; however the 62% decrease in
A375 VEGF expression and 14% decrease in YUZAZ6
VEGF expression were of borderline signiﬁcance (A375,
P=0.0586; YUZAZ6, P=0.0651). As in monolayer
cultures, resveratrol signiﬁcantly increased levels of p53 in
both of these wt p53 cell lines grown as spheroids (A375,
P=0.0270; YUZAZ6, P=0.0422). Resveratrol also
Fig. 5 Effect of resveratrol on expression of HIF-1a (a, e), VEGF
(b, f), p53 (c, g), or TSP1 (d, h) in A375 (a–d) or YUZAZ6
(e–g) spheroids. Cells were grown as a spheroid for a period of 72 h
and treated for an additional 72 h. Protein levels were determined by
ELISA. Performed in triplicate. Error bars represent ±SD
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123increased levels of TSP1 in both cell lines, with a trend
toward signiﬁcance (A375, P=0.1230; YUZAZ6, P=
0.1563).
The effect of resveratrol on endothelial cells
is facilitated by proteins secreted by melanoma
cells into the conditioned medium
We set out to demonstrate that the effect of resveratrol on
endothelial cells is not direct, but instead facilitated by
melanoma cells. Conditioned media from A375 melanoma
cells that were untreated or treated with resveratrol for 48 h
was collected and added to endothelial cells in monolayer
culture. We found that after a period of 72 h, endothelial
viability was signiﬁcantly decreased by 35% (P=0.0075)
(Fig. 6a).
Thrombospondin knockdown in melanoma cells
decreases the effect of resveratrol on endothelial cells
in three-dimensional culture
To show that the effect of resveratrol on endothelial cells in
co-culture was caused, in part, by thrombospondin, we
eliminated that variable by knocking down THBS1
expression in A375 cells. We determined by ELISA that
during these experiments, our non-silenced control cells
expressed 9.988 ng TSP1/mg protein whereas our THBS1
silenced cells expressed 2.928 ng TSP1/mg protein.
Angiogenesis was evaluated as a function of endothelial
cell survival in our three-dimensional spheroidal co-cul-
ture. We found that compared to their respective untreated
controls, resveratrol-treated endothelial cells co-cultured
with cells with knocked-down levels of THBS1 had
3.9-fold better survival than those co-cultured with control
transfected cells. This change was considered signiﬁcant
with a P-value of 0.0150 (Fig. 6b).
Discussion
Consistent with the ‘‘French Paradox’’ [38], we found that
resveratrol promoted proliferation of endothelial cells in
monolayer culture while resveratrol caused apoptosis in
HMVECs co-cultured with melanoma cells. Brakenhielm
and others have shown that resveratrol inhibits angiogen-
esis as well as processes dependent on angiogenesis, such
as wound healing and tumor growth [46–49, 61]. We
hypothesized that this anti-angiogenic activity was caused
by resveratrol’s modulation of VEC-stroma interactions or
more speciﬁcally, its induction of secreted matrix protein
TSP1 and inhibition of the elaboration of secreted matrix
protein VEGF by hypoxic cancer cells. These proteins,
when released into tumor stroma affect the delicate balance
between endothelial cell growth and death, thereby turning
off the angiogenic switch.
It has previously been shown that resveratrol upregulates
p53 [52–54] and downregulates both HIF-1a [49, 50] and
VEGF[50,51].OthershaveshownthatTSP1isregulatedby
p53andthatcellswithmutantp53havelowerlevelsofTSP1
expression [26, 61, 62]. Tumor hypoxia is known to stimu-
late tumor angiogenesis [63, 64]. In addition to studies with
normoxic cells, we worked with cells under hypoxic con-
ditions and in spheroids to more closely mimic in vivo
conditions. As expected, we found that hypoxia caused a
signiﬁcantincreaseinHIF-1alevels.Wefurtherfoundthata
dose of 50 lM resveratrol for a period of 48 h signiﬁcantly
decreased hypoxia-induced HIF-1a levels in all three cell
lines and alsosigniﬁcantly decreased baseline HIF-1alevels
in the M14 cell line. It has been well established that HIF-1a
upregulates VEGF [7–9]. We found that VEGF levels in
hypoxic and/or resveratrol treated cells strongly correlated
with HIF-1a protein expression levels.
Wt p53 has been shown to be stabilized under hypoxic
conditions [19, 20]. It has also been shown to be induced by
treatment with resveratrol, most likely as a function of
increased phosphorylation at serine 15 [52–54, 65–67]. We
Fig. 6 Effect of media conditioned by A375 melanoma cells treated
with resveratrol or untreated on endothelial cell viability in mono-
layer, as determined by XTT (a). Effect of THBS1 knockdown in
A375 melanoma cells on HMVEC response to resveratrol in a three-
dimensional co-culture model of tumor angiogenesis, as determined
by ﬂow cytometry. All data is expressed as a fraction of its respective
untreated control. Performed in triplicate. Error bars represent ±SD
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123foundthatwtp53levelswere increased inallcelllines when
placed under hypoxic conditions and/or when treated with a
dose of 50 lM resveratrol for a period of 48 or 72 h. Res-
veratrol-induced p53 accumulation under both normoxic
and hypoxic conditions was found to be signiﬁcant in the
A375 cell line. The TSP1 promoter has been found to be
positively regulated by wild-type p53 [21]. We found that
p53 was stabilized by resveratrol (Figs. 3, 4) suggesting the
wild-type form may be moreactive after drug treatment.We
also found that bax, another transcriptional target for wild-
type p53, was upregulated in melanoma after treatment with
resveratrol (data not shown). We therefore fully expected
that the effect on TSP1 (Figs. 3a–c, 6d, h) was transcrip-
tional. In fact, we found that treatment with resveratrol
caused an increase in THBS1 mRNA expression (Fig. 3e).
Resveratrol-mediated changes in p53 and TSP1 expression
levels were found to be dose and time dependent.
We believe that resveratrol acts as a multifactorial anti-
angiogenic agent by knocking down levels of HIF-1a pro-
tein, thereby suppressing HIF related pro-angiogenic factors
such as VEGF,and by stabilizing p53 protein levels,leading
to increased TSP1. To test this hypothesis, we looked at
endothelial cell response to resveratrol in our three-dimen-
sional co-culture model of angiogenesis. We found that
resveratrolcausedanincreaseinexpressionofp53andTSP1
and a decrease in expression of HIF-1a and VEGF in tumor
spheroids. When co-cultured with tumor cells in the spher-
oid model, resveratrol demonstrated an anti-angiogenic
effect on endothelial cells (Fig. 4). Conditioned media from
melanoma cells treated with resveratrol also caused a
decrease in HMVEC metabolic activity. This further con-
ﬁrms that the anti-angiogenic effect of resveratrol is caused
by a resveratrol-induced change in melanoma cell expres-
sion of secreted factors. In order to conﬁrm the role of
thrombospondin-1, we showed that knock-down of the
protein in A375 cells mitigated resveratrol’s effect on
endothelial cells in co-culture.We expect that the remaining
anti-angiogenic effect is caused, at least in part, by a
decrease in the secretion of the VEGF survival signal from
melanoma cells secondary to decreased HIF-1a.
We believe that it is the resveratrol-induced shift in
the TSP1-VEGF balance that is responsible for the change
in HMVEC survival that we see in the 3D model after
treatment with resveratrol or in monolayer culture after
treatment with resveratrol-induced melanoma conditioned
media. These data show the importance of matrix interac-
tions and cell–cell interactions in determining VEC
response to resveratrol and the value of using angiogenesis
models that incorporate a tumor compartment.
Angiogenesis is critical for cancer development and
progression.Recentapprovalofanti-angiogenesisagentsfor
the treatment of colon, breast, lung, and kidney cancer
demonstrates the clinical value of this therapeutic modality.
In this paper, we showed that resveratrol caused prolifera-
tionofendothelialcellsinmonolayerculture,butactedasan
anti-angiogenic agent in a three-dimensional co-culture
model of tumor angiogenesis, likely through downregula-
tion of VEGF and upregulation of TSP1. This experimental
in vitro system has intrinsic limitations due to the lack of
other physiologic process encountered in vivo, potentially
limiting its clinical applicability. The limited bioavailability
of resveratrol could potentially further limit the clinical
applicability of these ﬁndings. Bioavailability of unmetab-
olized resveratrol in humans is relatively low with an
average AUC of 1,319 ng h/ml (5.8 h lM) and average
maximumconcentrationof51.90 ng/ml(227 nM)lastingan
average of 1.5 h after a 5 g dose of resveratrol in the form of
uncoated immediate-release caplets. On the other hand, a
novel resveratrol formulation,SRT501developed by Sirtris,
possesses roughly ﬁve times higher bioavailability than
native resveratrol [68]. In a phase I trial of oral dosing of 5 g
per day for 7 days, SRT501 produced blood levels of
approximately 10 lM without toxicity, with AUC values of
44 h lM, comparable to those with demonstrated activity in
vitro [69]. In addition, metabolites of resveratrol, such as
glucouronide 1 and 2 and 3-sulfate forms are 6.4–23.49
more bioavailable, in terms of AUC, at the same intake dose
[70]. It is possible that one or more of these metabolites
would have a similar effect as unmetabolized resveratrol. In
fact, we have found that trans-resveratrol-3-o-b-d-glucur-
onide has a similar anti-melanoma effect as unmetabolized
resveratrol (data not shown). Patient tolerance for resvera-
trol is excellent and dose escalation studies of resveratrol
that have shown that adverse events caused by resveratrol
are nearly non-existent. Further, most pharmacokinetic
studies have looked at single doses of resveratrol [70], yet
resveratrol can be taken daily and this may increase circu-
lating blood levels. Newer resveratrol dosing formulations
appear to reach in vivo exposures comparable to those
employed in our study. Cancer trials are currently underway
with SRT501. Our ﬁndings suggest that measurement of
tumor or circulating serum levels of VEGF and TSP1 in
cancer patients receiving resveratrol may be worthy of
further study as potential biomarkers of resveratrol’s
anti-angiogenic activity.
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